Comparison of Efficacy and Safety of Recombinant Tissue Plasminogen Activator in Intravenous Thrombolysis for Cardiogenic and Non-cardiogenic Cerebral Infarction
CAO Li, et al
Anqing Hospital Affiliated to Anhui Medical University, Anhui Anqing 246000, China
Abstract：Objective: To compare the efficacy and safety of recombinant tissue plasminogen activator (rt-PA) in intravenous thrombolysis for cardiogenic cerebral infarction (CCI) and non-cardiogenic cerebral infarction (NCI). Methods: Retrospective study was conducted to collect the clinical data of 60 patients with hyperacute cerebral infarction treated by rt-PA intravenous thrombolysis from January 2017 to December 2018 in our hospital, and they were divided into NCI group (24 cases) and CCI group (36 cases). The differences of National Institutes of Health Stroke Scale (NIHSS) and modified Rankin scale (mRS) scores and adverse events before and after treatment were compared between the two groups. Results: Compared with before treatment, NIHSS scale scores of both groups were significantly decreased after treatment (P<0.01). The NIHSS scale scores of CCI group before, 1 day after and 7 days after treatment were not statistically significant compared with those of NCI group (P>0.05). After treatment, mRS scale scores of the two groups were significantly lower than before treatment (P<0.01). There was no significant difference in mRS scale between CCI group and NCI group before, 1 month after and 3 months after treatment (P>0.05). There was no significant difference between the two groups in the prognosis at 3 months after treatment (P>0.05). There was no statistical significance in the comparison of reinfarction, asymptomatic cerebral hemorrhage, symptomatic cerebral hemorrhage and mortality between the two groups (P>0.05). The incidence of skin mucosal bleeding and brain hernia in CCI group was significantly higher than that in NCI group (P<0.05). Conclusions: Rt-pa intravenous thrombolytic therapy in hyperacute CCI and NCI patients within 4.5h can effectively alleviate neurological defects, and the prognosis of patients is effective. The overall efficacy and prognosis effect of the two are similar, but the risk of bleeding and adverse events after thrombolysis in CCI patients is significantly increased.
曹莉, 张玉琴, 王雷, 汪梦琳. 重组组织型纤溶酶原激活剂静脉溶栓治疗心源性与非心源性脑梗死的疗效及安全性对比[J]. 河北医学, 2019, 25(12): 1954-1957.
CAO Li, et al. Comparison of Efficacy and Safety of Recombinant Tissue Plasminogen Activator in Intravenous Thrombolysis for Cardiogenic and Non-cardiogenic Cerebral Infarction. HeBei Med, 2019, 25(12): 1954-1957.
[1] 石文芳.超急性期脑梗死患者低剂量rt-PA静脉溶栓临床观察[J].中国实用神经疾病杂志,2017,20(15):70~72. [2] 赵秀欣,穆利春,马丽芳,等.rt-PA静脉溶栓治疗急性脑梗死临床分析[J].中国循证心血管医学杂志,2016,8(4):486~488. [3] Lyden P. Using the national institutes of health stroke scale: a cautionary tale[J]. Stroke,2017,48(2):513~519. [4] Dewilde S, Annemans L, Peeters A, et al. Modified rankin scale as a determinant of direct medical costs after stroke[J]. Int Stroke,2017,12(4):392~400. [5] 李蒙蒙,朱明肃,李轩,等.急性脑梗死患者血清胆红素、同型半胱氨酸与颈动脉粥样硬化斑块性质的关系[J].医学研究与教育,2019,36(1):13~16,33. [6] 李江涛,刘荣丽,王润青,等.急性脑梗死不同时间窗内阿替普酶静脉溶栓治疗效果[J].中国合理用药探索,2019,16(1):30~33. [7] 史桂芬,张素琴,许宏洲,等.平均血小板容积对rtPA静脉溶栓治疗的缺血性脑卒中病人预后的预测价值[J].蚌埠医学院学报,2018,43(11):1501~1504. [8] 樊敬峰.静脉溶栓对脑梗死患者血浆[脂蛋白(a)]D-二聚体水平变化影响的研究[J].河北医学,2018,24(4):564~567. [9] 傅懋林,张永刚,肖雪玲,等.重组组织型纤溶酶原激活剂动脉内接触性溶栓治疗心源性脑栓塞的疗效观察[J].中西医结合心脑血管病杂志,2019,17(3):449~452.
2019, Vol. 25 
冀公网安备13080202000677号